A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)

Multiple Sclerosis Journal

Volumn 19, Issue 10, 2013, Pages 1371-1380

  Carroll, W M ^a   Saida, T ^b   Kim, H J ^c   Kira, J ^d   Kermode, A G ^a   Tsai, C P ^e,k   Fujihara, K ^f   Kusunoki, S ^g   Tanaka, M ^h   Kim, K K ⁱ   Bates, D ^j  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b Kansai Multiple Sclerosis Center   (Japan)

^c National Cancer Center   (South Korea)

^d KYUSHU UNIVERSITY   (Japan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h UTANO NATIONAL HOSPITAL   (Japan)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k NATIONAL YANG MING UNIVERSITY   (Taiwan)

more..

Author keywords

Asia; diagnosis; interferon beta; Multiple sclerosis; neuromyelitis optica

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; GADOLINIUM; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

CLINICAL DECISION MAKING; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DIFFUSION WEIGHTED IMAGING; DRUG INDICATION; DRUG MEGADOSE; EARLY INTERVENTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRACTICE GUIDELINE; REVIEW;

ASIA; DIAGNOSIS; INTERFERON BETA; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

ALGORITHMS; HUMANS; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; SECONDARY PREVENTION;

EID: 84883164828     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512471092     Document Type: Review

References (67)

1. World Health Organization. Atlas multiple sclerosis resources in the world 2008. http://www.who.int/mental-health/neurology/Atlas-MS-WEB.pdf (2008, accessed 5 May 2011).
2. Bichuetti DB, Lobato de, Oliveira EM, et al. Neuromyelitis optica treatment: Analysis of 36 patients. Arch Neurol. 2010 ; 67: 1131-1136
3. Cabre P, Gonzalez-Quevedo A, Lannuzel A, et al. Descriptive epidemiology of neuromyelitis optica in the Caribbean basin [article in French]. Rev Neurol (Paris). 2009 ; 165: 676-683
4. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012 ; 135: 1834-1849
5. Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M, et al. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry. 2002 ; 73: 429-435
6. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006 ; 66: 678-684
7. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006 ; 67: 1242-1249
8. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet. 2007 ; 370: 389-397
9. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009 ; 8: 987-997
10. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet. 2001 ; 357: 1576-1582
11. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet. 2009 ; 374: 1503-1511
12. Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol. 2010 ; 12: 244-255
13. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000 ; 343: 898-904
14. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology. 2012 ; 78: 1315-1322
15. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993 ; 43: 655-661
16. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993 ; 43: 662-667
17. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 ; 39: 285-294
18. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol. 1998 ; 43: 79-87
19. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995 ; 45: 1268-1276
20. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001 ; 49: 290-297
21. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998 ; 352: 1498-1504
22. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Ann Neurol. 1999 ; 46: 197-206
23. Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012 ; 18: 108-112
24. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012 ; 69: 239-245
25. Qian P, Cross AH, Naismith RT. Lack of response to monoclonal antibody therapy in neuromyelitis optica. Arch Neurol. 2011 ; 68: 1207-1209
26. Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. 2008 ; 255: 305-307
27. Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?. Mult Scler. 2012 ; 18: 1480-1483
28. Uzawa A, Mori M, Hayakawa S, et al. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol. 2010 ; 17: 672-676
29. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007 ; 13: 256-259
30. Tanaka M, Tanaka K, Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol. 2009 ; 62: 167-170
31. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 ; 58: 169-178
32. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
33. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
34. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010 ; 17: 1019-1032
35. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain. 2007 ; 130: 1206-1223
36. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol. 2008 ; 255: 163-170
37. O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996 ; 60: 382-387
38. Nakajima H, Hosokawa T, Sugino M, et al. Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol. 2010 ; 10: 45.
39. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005 ; 65: 1479-1482
40. Kobayashi Z, Tsuchiya K, Uchihara T, et al. Intractable hiccup caused by medulla oblongata lesions: A study of an autopsy patient with possible neuromyelitis optica. J Neurol Sci. 2009 ; 285: 241-245
41. Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and pathogenic implications. Neurology. 2011 ; 76: 1229-1237
42. Lu Z, Zhang B, Qiu W, et al. Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. PLoS One. 2011 ; 6: e22766
43. Wandinger KP, Stangel M, Witte T, et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum. 2010 ; 62: 1198-1200
44. Kale N, Icen M, Agaoglu J, et al. Clustering of organ-specific autoimmunity: A case presentation of multiple sclerosis and connective tissue disorders. Neurol Sci. 2008 ; 29: 471-475
45. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008 ; 65: 78-83
46. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 ; 6: 805-815
47. Nozaki I, Hamaguchi T, Komai K, et al. Fulminant Devic disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry. 2006 ; 77: 1094-1095
48. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010 ; 6: 383-392
49. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999 ; 53: 1107-1114
50. Kanzaki M, Mochizuki H, Ogawa G, et al. Clinical features of opticospinal multiple sclerosis with anti-aquaporin 4 antibody. Eur Neurol. 2008 ; 60: 37-42
51. Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: Clinical, neuroimaging and immunogenetic studies. Brain. 1999 ; 122: 1689-1696
52. Baba T, Nakashima I, Kanbayashi T, et al. Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol. 2009 ; 256: 287-288
53. Kanbayashi T, Shimohata T, Nakashima I, et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: New neurochemical and immunological implications. Arch Neurol. 2009 ; 66: 1563-1566
54. Qiu W, Raven S, Wu JS, et al. Hypothalamic lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 ; 82: 819-822
55. Matsushita T, Isobe N, Piao H, et al. Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status. J Neurol Sci. 2010 ; 291: 37-43
56. Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler. 2010 ; 16: 1229-1236
57. Saiki S, Ueno Y, Moritani T, et al. Extensive hemispheric lesions with radiological evidence of blood-brain barrier integrity in a patient with neuromyelitis optica. J Neurol Sci. 2009 ; 284: 217-219
58. Ito S, Mori M, Makino T, et al. 'Cloud-like enhancement' is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol. 2009 ; 66: 425-428
59. Wei Q, Bundell C, Wu JS, et al. Low level of systemic autoimmunity in Western Australian multiple sclerosis patients. Mult Scler. 2010 ; 16: 351-354
60. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement. Arch Neurol. 2005 ; 62: 865-870
61. Kikuchi S, Fukazawa T, Niino M, et al. HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands. Human leukocyte antigen. Neurology. 2003 ; 60: 647-651
62. Nakashima I, Fujihara K, Sato S, et al. Oligoclonal IgG bands in Japanese patients with multiple sclerosis. A comparative study between isoelectric focusing with IgG immunofixation and high-resolution agarose gel electrophoresis. J Neuroimmunol. 2005 ; 159: 133-136
63. Wu JS, Qiu W, Castley A, et al. Presence of CSF oligoclonal bands (OCB) is associated with the HLA-DRB1 genotype in a West Australian multiple sclerosis cohort. J Neurol Sci. 2010 ; 288: 63-67
64. Tintore M, Rovira A, Rio J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology. 2008 ; 70: 1079-1083
65. Saida T, Tashiro K, Itoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology. 2005 ; 64: 621-630
66. Siritho S, Nakashima I, Takahashi T, et al. AQP4 antibody-positive Thai cases: Clinical features and diagnostic problems. Neurology. 2011 ; 77: 827-834
67. Weinshenker BG, Carroll WM. Does detection of anti-AQP4 antibodies trump clinical criteria for neuromyelitis optica?. Neurology. 2011 ; 77: 812-813